Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any acute myeloid leukemia that has the chromosomal anomaly t(6;9)(p23;q34.1). (A cytogenetic abnormality that refers to the translocation of the short arm (p23) of chromosome 6 and the long arm (q34.1) of chromosome 9. It is associated with DEK/NUP214 fusions, acute myeloid leukemia and myelodysplastic syndromes.)
No clinical trials have been registered for acute myeloid leukemia, t(6;9)(p23;q34.1).
1 publication has been identified in PubMed for acute myeloid leukemia, t(6;9)(p23;q34.1). Research spans Gene Therapy / Novel Therapeutics (100%).
Csizmar CM (2024). [PMID: 38899336](https://pubmed.ncbi.nlm.nih.gov/38899336/). *Haematologica*. [Gene Therapy / Novel Therapeutics]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:43 AM UTC
Common questions about acute myeloid leukemia, t(6;9)(p23;q34.1)